This data presentation supports BRIUMVI’s real-world use but does not represent a new regulatory or commercial catalyst. Monitor upcoming quarterly sales figures for signs of market penetration trends. No immediate revenue inflection expected from this release.
Price Chart
Executive Summary
TG Therapeutics announced new real-world and dosing data for BRIUMVI® (ublituximab-xiiy) in relapsing multiple sclerosis (RMS) at the 2026 American Academy of Neurology meeting. The ENABLE and ENHANCE studies provide additional evidence on safety, tolerability, and optimized IV dosing, supporting BRIUMVI's clinical profile.
Key Facts
- Presented new data from the ENABLE (Phase 4 observational) and ENHANCE (dosing optimization) studies at AAN 2026.
- Data focus on real-world effectiveness, safety, and tolerability of BRIUMVI in RMS patients.
- No new efficacy endpoints, clinical trial results, or regulatory decisions announced.
- BRIUMVI is already FDA-approved for adults with RMS, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.
Financial Impact
Limited near-term financial impact; reinforces existing commercial positioning without new revenue catalysts.
Risk Factors
- BRIUMVI faces competition from established anti-CD20 therapies like Ocrevus.
- Safety risks include PML, HBV reactivation, and infusion reactions, which may limit prescribing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3278846 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | SC 13G/A | $54.10 | awaiting T+60 | — | $56.44 (+4.33%) |
Aug 3, 2026 12w ago | 8-K | $46.17 $55.99 | ▲ +21.27% | ▲ +19.49% | $56.44 (+22.24%) |
Jun 11, 2026 19w ago | Institutional Cluster | $49.52 $55.74 | ▲ +12.56% | ▲ +9.30% | $56.44 (+13.97%) |
Jun 3, 2026 20w ago | 8-K | $40.11 $55.72 | ▲ +38.92% | ▲ +36.42% | $56.44 (+40.71%) |
Jun 3, 2026 20w ago | Press Release | $40.11 $55.72 | ▲ +38.92% | ▲ +36.42% | $56.44 (+40.71%) |
Jun 1, 2026 21w ago | Press Release | $37.41 $55.42 | ▲ +48.14% | ▲ +46.91% | $56.44 (+50.87%) |
May 27, 2026 21w ago | 8-K | $38.82 $54.27 | ▲ +39.80% | ▲ +38.06% | $56.44 (+45.39%) |
May 6, 2026 24w ago | 8-K | $41.97 $52.03 | ▲ +23.97% | ▲ +21.91% | $56.44 (+34.48%) |
Apr 30, 2026 25w ago | Press Release | $33.78 $55.75 | ▲ +65.04% | ▲ +61.93% | $56.44 (+67.08%) |
Apr 22, 2026 26w ago | Press Release | $38.31 $54.87 | ▲ +43.23% | ▲ +38.45% | $56.44 (+47.32%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers